August 6, 2020 10:25 AM EDT
R&D

Pfiz­er's Lor­bre­na bests Xalko­ri in PhI­II read­out — is it a po­ten­tial suc­ces­sor?

Max Gelman

Senior Editor

Pfiz­er has long pinned hopes on lor­la­tinib as be­ing a suc­ces­sor to Xalko­ri for ALK-pos­i­tive non-small cell lung can­cer, and the phar­ma re­leased da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump an­nounces picks for FDA, CDC; No­var­tis seeks bolt-on deals, rais­es guid­ance; RFK Jr., Elon Musk may find ...

For CDC, Trump picks Dave Wel­don, a for­mer con­gress­man who pushed for vac­cine in­jury claims

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times